XML 17 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
Liquidity and Capital Resources (Details) (USD $)
3 Months Ended
Mar. 31, 2013
Dec. 31, 2012
Mar. 31, 2012
Dec. 31, 2011
Estimated projected expenditure [Line Items]        
Cash and cash equivalents $ 11,429,671 $ 14,344,088 $ 16,916,696 $ 17,988,590
Marketable securities 21,000,000 24,000,000    
Currently projected expenditures for clinical programs 21,100,000      
Aldoxorubicin [Member]
       
Estimated projected expenditure [Line Items]        
Currently projected expenditures for clinical programs 7,700,000      
Bafetinib [Member]
       
Estimated projected expenditure [Line Items]        
Currently projected expenditures for clinical programs 100,000      
Tamibarotene [Member]
       
Estimated projected expenditure [Line Items]        
Currently projected expenditures for clinical programs 1,800,000      
General Operation [Member]
       
Estimated projected expenditure [Line Items]        
Currently projected expenditures for clinical programs 4,800,000      
Other General and Administrative Expenses [Member]
       
Estimated projected expenditure [Line Items]        
Currently projected expenditures for clinical programs $ 6,800,000